This is a condition where amyloid, a type of protein, builds up in the walls of small blood vessels in the brain. This can cause bleeding in the brain, reduced blood flow, and strokes. It's different from the amyloid buildup seen in Alzheimer's disease.
Every report comes from a Lived member, sent anonymously.
Have you tried High Blood Pressure Medications for Cerebral Amyloid Angiopathy?
Cerebral amyloid angiopathy (CAA) is a disease of the small blood vessels in the brain. A protein called amyloid-beta slowly builds up in the walls of small arteries on the brain's surface and in its outer layer, the cortex. Over many years, those vessel walls weaken and become fragile, so they can leak or break. The best-known consequence is bleeding into the brain, a type of stroke called an intracerebral hemorrhage. Bleeds from CAA tend to happen in the outer parts of the brain rather than deep inside it, and CAA is one of the main causes of this kind of bleed in older adults. CAA can also cause tiny bleeds that produce no symptoms, brief spells of numbness, weakness or speech trouble that come and go, and gradual problems with thinking, such as slower processing and difficulty planning. CAA is closely related to Alzheimer's disease, which involves the same protein, and the two often occur together. It is different from the forms of amyloidosis in which other amyloid proteins build up in organs such as the heart and kidneys.
Age is the main risk factor. Common CAA affects middle-aged and older adults, and the changes in the vessel walls develop silently over two to three decades before any bleeding appears. Researchers think part of the problem is that the aging brain drains amyloid-beta less efficiently, so the protein becomes trapped in the vessel walls. Genes also play a part. Variants of the APOE (apolipoprotein E) gene, the same gene linked to Alzheimer's risk, are the most important common genetic influence: the e4 form is associated with more amyloid buildup, and the e2 form with more fragile vessels and bleeding. Carrying one of these variants raises the likelihood of CAA but does not mean someone will develop it. High blood pressure does not cause CAA, but higher readings are linked to a greater chance that fragile vessels will bleed. Rarer forms begin earlier in life. Hereditary CAA is caused by specific gene changes passed down in families and often causes strokes or dementia starting in mid-adulthood. A small number of people develop CAA two or three decades after brain surgery in childhood or treatment with growth hormone taken from human donors, which is thought to have transferred amyloid-beta. This is called iatrogenic CAA, meaning it was caused by a medical treatment.
CAA is usually diagnosed from a brain MRI, interpreted alongside the person's age, symptoms and history. MRI sequences that are sensitive to blood can show microbleeds, tiny old bleeds scattered in the outer parts of the brain, and cortical superficial siderosis, a thin coating of old blood over the brain's surface. Larger past bleeds and certain changes in the brain's white matter add to the picture. Doctors use a tested set of these findings, called the Boston criteria, to classify CAA as possible or probable. A CT scan, often the first test after a sudden bleed, can suggest CAA but cannot show microbleeds. A definite diagnosis requires examining brain tissue under a microscope. Because MRI is usually enough, a brain biopsy is uncommon and tends to be reserved for unusual situations, such as suspected inflammation that is not improving with treatment. Many people come to attention because of memory problems or brief spells of neurological symptoms, so part of the assessment is telling CAA apart from other causes. These spells can look like transient ischemic attacks (mini-strokes caused by a temporarily blocked artery), and the difference matters: the usual mini-stroke treatment is a blood-thinning medicine, which should not be started or increased for CAA spells. Spinal fluid tests, amyloid PET scans and APOE testing are sometimes used in specialist centers when the picture is unclear or overlaps with Alzheimer's disease. An amyloid PET scan cannot tell amyloid in vessel walls apart from Alzheimer's plaques, so it does not settle the diagnosis by itself.
There is currently no cure for CAA and no treatment that removes amyloid from the vessels or halts the disease. Care focuses on lowering the chance of a brain bleed, treating bleeds and other complications when they occur, and supporting thinking and daily life. Blood pressure control is the most important step. A reading has a top number (systolic, the pressure as the heart beats) and a bottom number (diastolic, the pressure between beats). Specialists generally aim lower than usual for people with CAA, and one widely used practical review suggests keeping blood pressure below 120/80, meaning a top number under 120 and a bottom number under 80. The right target depends on the person and is set with their clinician. Medicines that affect clotting need careful review. Anticoagulants (blood thinners such as warfarin or apixaban) raise the risk of brain bleeding, so long-term use is avoided where possible, and widespread superficial siderosis on MRI is generally treated as a reason not to use them. Aspirin and similar antiplatelet medicines are usually avoided when taken only to prevent a first heart attack or stroke, but may still be worth continuing when there is a clear reason, such as after a heart attack or an ischemic stroke caused by a blocked artery. For people with atrial fibrillation, an irregular heart rhythm that normally calls for a blood thinner, a procedure that closes off the left atrial appendage (a small pouch in the heart where most of these clots form) may be an alternative. These choices are individual and usually involve neurology and cardiology together. After a CAA-related bleed, specialists advise avoiding nonsteroidal anti-inflammatory drugs (NSAIDs), a group of pain relievers that includes ibuprofen, because they may raise the risk of another bleed. Cholesterol-lowering statins are generally continued when there is a clear heart or stroke reason for them, with the trade-offs discussed for people at higher bleeding risk. A brain bleed itself is treated like other brain hemorrhages: stopping blood thinners, lowering blood pressure, controlling swelling and sometimes surgery, followed by rehabilitation. Memory and thinking problems are sometimes treated with Alzheimer's medicines such as donepezil (Aricept), which offer modest benefit at best in CAA. A rare form called CAA-related inflammation, in which the immune system reacts to the amyloid, is treated with corticosteroids and often improves. MRI findings of CAA also matter for newer anti-amyloid Alzheimer's drugs such as lecanemab (Leqembi). These findings raise the risk of brain swelling and bleeding with those treatments, so they are weighed carefully before treatment is offered.
CAA usually develops slowly over many years, and its course varies widely. Some people learn they have it from an MRI done because of mild memory problems or brief neurological spells; others find out only after a bleed. Knowing early is useful because it changes decisions about blood pressure and blood-thinning medicines before a major bleed happens. The chance of bleeding is the central long-term concern, and it depends on what the MRI shows. In one study of people with microbleeds but no previous major bleed, about 5 in 100 had a brain bleed each year. After a first CAA-related bleed, the yearly chance of another is roughly 10 in 100, and it is higher when superficial siderosis is widespread. These figures come from specialist centers and describe groups, not any one person's future. Recovery after a bleed depends on its size and location and often involves rehabilitation. Thinking problems can gradually worsen over time, and many people with CAA also have Alzheimer's changes that contribute. Follow-up usually includes regular blood pressure checks, review of any medicine that affects bleeding, and attention to memory and daily function. Because many treatments for other conditions, including some emergency stroke treatments, can raise bleeding risk, it helps for every clinician involved in care to know about the diagnosis. Hereditary forms follow a different course, beginning earlier and often progressing faster, and genetic counseling can help families understand what the diagnosis means for relatives.
Arrange a medical evaluation if memory or thinking changes are affecting daily life, or if an MRI report mentions microbleeds or superficial siderosis and no one has explained what it means. Check with the clinician managing your CAA before starting or stopping a blood thinner, aspirin or regular anti-inflammatory pain relievers. Contact your care team the same day about brief spells of numbness, tingling, weakness, vision changes or speech trouble that have already passed, so the cause can be checked before any medicine is changed. Call promptly about new headaches, seizures, or confusion that builds over days to weeks, which can signal the inflammatory form of CAA. Call 911 for signs of a brain bleed or stroke that are happening now: sudden numbness or weakness of the face, arm or leg, sudden confusion or trouble speaking, sudden trouble seeing or walking, or a sudden severe headache with no known cause. Tell the emergency team about the CAA diagnosis.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Cerebral Amyloid Angiopathy is like, what's helped you, or ask the community a question.